Dianthus Therapeutics to Present Two Posters on DNTH103 at 2024 AANEM Meeting

Dianthus Therapeutics, Inc., a clinical-stage biotechnology firm with a focus on antibody complement therapeutics for severe autoimmune diseases, has unveiled two poster presentations for its investigational drug DNTH103 at the 2024 American Association of Neuromuscular and Electrodiagnostic Medicine (AANEM) Annual Meeting. The conference is being held from October 15-18, 2024, in Savannah, Georgia.

DNTH103 is a unique classical pathway inhibitor that specifically targets the active form of C1s. It is currently under evaluation as a treatment for generalized Myasthenia Gravis, Multifocal Motor Neuropathy, and Chronic Inflammatory Demyelinating Polyneuropathy. The drug aims to offer a low-volume, convenient, and safe therapeutic option.

The first poster presentation, scheduled for October 16, 2024, from 6:15-6:45 PM ET, and October 17, 2024, from 2:45-3:15 PM ET, focuses on the sustainable inhibition of complement and prevention of nerve conduction velocity impairment in a preclinical model of Chronic Inflammatory Demyelinating Polyneuropathy (CIDP). This poster (#201) highlights preclinical and in vitro data that describe the unique profile of DNTH103 in disease models of generalized Myasthenia Gravis (gMG) and CIDP, comparing its head-to-head affinity and pharmacodynamic potency against riliprubart.

The second poster, to be presented on October 16, 2024, from 6:15-6:45 PM ET, and October 17, 2024, from 9:30-10:00 AM ET, discusses DNTH103 as a potentially safer and more convenient novel therapy for generalized Myasthenia Gravis. Poster (#297) will also be available in the Scientific Publications section of the Dianthus website following the presentations.

DNTH103 is an investigational monoclonal antibody designed to selectively inhibit only the active form of the C1s protein, a key component in the classical complement pathway. It features YTE half-life extension technology, enabling subcutaneous, self-administered injections that can be dosed as infrequently as once every two weeks. The selective inhibition of the classical pathway is intended to reduce the risk of infection from encapsulated bacteria by preserving the immune activity of the lectin and alternative pathways. Given the significant role of the classical pathway in various autoimmune diseases, DNTH103 holds the potential to emerge as a best-in-class product across numerous autoimmune conditions with high unmet needs.

Dianthus Therapeutics is actively building a neuromuscular franchise with DNTH103. The company initiated the Phase 2 MaGic trial for generalized Myasthenia Gravis in the first quarter of 2024 and the Phase 2 MoMeNtum trial for Multifocal Motor Neuropathy in the third quarter of 2024. Additionally, a Phase 2 trial for Chronic Inflammatory Demyelinating Polyneuropathy is planned for the second half of 2024. However, DNTH103 is still investigational and has not been approved as a therapy in any jurisdiction worldwide.

Dianthus Therapeutics is headquartered in New York City and Waltham, Mass. The company is led by an experienced team of biotech and pharma executives focused on developing next-generation antibody complement therapeutics. Their mission is to deliver transformative treatments for individuals suffering from severe autoimmune and inflammatory diseases.